These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18627337)

  • 41. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
    Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of clobetasol spray: factors beyond patient compliance.
    Bhutani T; Koo J; Maibach HI
    J Dermatolog Treat; 2012 Feb; 23(1):11-5. PubMed ID: 21254848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis.
    Lowe N; Feldman SR; Sherer D; Weiss J; Shavin JS; Lin YL; Foley V; Soto P
    J Dermatolog Treat; 2005 Aug; 16(3):158-64. PubMed ID: 16096182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ultrasound evaluation of clobetasol propionate 0.05% foam application in psoriatic and healthy skin: a pilot study.
    Lacarrubba F; Nardone B; Musumeci ML; Micali G
    Dermatol Ther; 2009 Nov; 22 Suppl 1():S19-21. PubMed ID: 19891687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone.
    Volden G; Kragballe K; Van De Kerkhof PC; Aberg K; White RJ
    J Dermatolog Treat; 2001 Sep; 12(3):141-4. PubMed ID: 12243704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis.
    Lebwohl M; Colón LE
    Cutis; 2007 Nov; 80(5 Suppl):29-40. PubMed ID: 18154221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials.
    Ramachandran V; Bertus B; Bashyam AM; Feldman SR
    Ann Pharmacother; 2020 Sep; 54(9):872-878. PubMed ID: 32126800
    [No Abstract]   [Full Text] [Related]  

  • 48. Clobetasol propionate foam, 0.05%.
    Melian EB; Spencer CM; Jarvis B
    Am J Clin Dermatol; 2001; 2(2):89-92; discussion 93. PubMed ID: 11705308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clobetasol propionate for psoriasis: are ointments really more potent?
    Warino L; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2006 Jun; 5(6):527-32. PubMed ID: 16774104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis.
    Jorizzo JL; Magee K; Stewart DM; Lebwohl MG; Rajagopalan R; Brown JJ
    Cutis; 1997 Jul; 60(1):55-60. PubMed ID: 9252738
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination topical therapy for the treatment of psoriasis.
    Del Rosso Do JQ
    J Drugs Dermatol; 2006 Mar; 5(3):232-4. PubMed ID: 16573255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
    Andres P; Poncet M; Farzaneh S; Soto P
    J Drugs Dermatol; 2006 Apr; 5(4):328-32. PubMed ID: 16673799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double-blind comparison between two new topical corticosteroids, halcinonide 0.1% and clobetasol propionate cream 0.05%.
    Bleeker J
    Curr Med Res Opin; 1975; 3(4):225-8. PubMed ID: 1097198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis.
    Hudson CP; Kempers S; Menter A; Papp K; Smith S; Sofen H; Colón LE; Johnson LA; Gottschalk R
    Cutis; 2011 Oct; 88(4):201-7. PubMed ID: 22106730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
    Beutner K; Chakrabarty A; Lemke S; Yu K
    J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial.
    Menter A
    Cutis; 2007 Nov; 80(5 Suppl):12-9. PubMed ID: 18154219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis.
    Wolkerstorfer A; Strobos MA; Glazenburg EJ; Mulder PG; Oranje AP
    J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):226-31. PubMed ID: 9704834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial.
    Lenane P; Macarthur C; Parkin PC; Krafchik B; DeGroot J; Khambalia A; Pope E
    JAMA Dermatol; 2014 Jan; 150(1):47-50. PubMed ID: 24226568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical tacrolimus for atopic dermatitis.
    Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Topical Corticosteroid Concerns Among Parents of Children with Psoriasis versus Atopic Dermatitis: A French Multicenter Cross-Sectional Study.
    Moawad S; Mahé E; Aubert-Wastiaux H; Phan A; Maruani A; Chiaverini C; Bodemer C; Mazereeuw-Hautier J; Lasek-Duriez A; Droitcourt C; Barbarot S; Beauchet A; Bursztejn AC;
    Am J Clin Dermatol; 2018 Apr; 19(2):261-265. PubMed ID: 28849428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.